Phase I/II 225Ac-J591 Plus 177Lu-PSMA-I&T for Progressive Metastatic Castration Resistant Prostate Cancer

Status: Suspended

Phase of Trial: Phase I/II

Latest Information Update: 01 Aug 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ATL 101 Telix Pharmaceuticals (Primary) ; Lutetium-177-PSMA-imaging-and-therapy (Primary)
Indications Adenocarcinoma; Bone metastases; Liver metastases; Prostate cancer
Focus Adverse reactions

30 Jul 2024 Planned End Date changed from 27 Dec 2027 to 31 Dec 2027.
30 Jul 2024 Planned primary completion date changed from 24 Dec 2024 to 24 Dec 2025.
15 Aug 2023 Planned number of patients changed from 33 to 48.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com